Laurus Labs Limited (BOM:540222)

Market Cap	467.00B
Revenue (ttm)	59.29B
Net Income (ttm)	5.09B
Shares Out	n/a
EPS (ttm)	9.45
PE Ratio	91.78
Forward PE	67.14
Dividend	1.20 (0.14%)
Ex-Dividend Date	May 9, 2025

Volume	240,644
Average Volume	75,436
Open	858.25
Previous Close	858.25
Day's Range	848.70 - 875.40
52-Week Range	422.70 - 944.00
Beta	n/a
RSI	48.07
Earnings Date	Oct 20, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,167
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.